Predictors of ICS/LABA prescribing in COPD patients: A study from general practice

BMC Family Practice

Volumn 15, Issue 1, 2014, Pages

  Drivenes, Elin ^a   Østrem, Anders ^b   Melbye, Hasse ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

COPD; Corticosteroids; Prescription; Primary care

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

ADULT; AGED; ASTHMA; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CROSS-SECTIONAL STUDY; DRUG COMBINATION; EPIDEMIOLOGY; FEMALE; FORCED EXPIRATORY VOLUME; GENERAL PRACTICE; HUMAN; INAPPROPRIATE PRESCRIBING; INHALATIONAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; NORWAY; PHYSIOLOGY; PRACTICE GUIDELINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; STANDARDS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TRENDS; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; ASTHMA; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; FEMALE; FORCED EXPIRATORY VOLUME; GUIDELINE ADHERENCE; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; MIDDLE AGED; NORWAY; PHYSICIAN'S PRACTICE PATTERNS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84898790981     PISSN: None     EISSN: 14712296     Source Type: Journal    
DOI: 10.1186/1471-2296-15-42     Document Type: Article

References (24)

1. the Global initiative for Chronic Obstructive Lung Disease. GOLD, 2012 http://www.goldcopd.org/uploads/users/files/GOLD-Report-2013-Feb20.pdf
2. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Miravitlles M, Anzueto A, Int J Chron Obstruct Pulmon Dis 2009 4 185 201 19516917
3. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE, Am Rev Respir Dis 1990 142 832 836 10.1164/ajrccm/142.4.832 2221590
4. Global Strategy for Diagnosis, Management, and Prevention of COPD. GOLD, 2010 http://www.goldcopd.org/uploads/users/files/GOLDReport2006-0122.pdf
5. Susceptibility to exacerbation in chronic obstructive pulmonary disease. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Maacnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA, N Engl J Med 2010 363 1128 1138 10.1056/NEJMoa0909883 20843247
6. Geographic differences in clinical characteristics and management of COPD: the EPOCA study. Miravitlles M, Murio C, Tirado-Conde G, Levy G, Muellerova H, Soriano JB, Ramirez-Venegas A, Ko FW, Canelos-Estrella B, Giugno E, Bergna M, Cherrez I, Anzueto A, Int J Chron Obstruct Pulmon Dis 2008 3 803 814 19281096
7. Development, validity and responsiveness of the Clinical COPD Questionnaire. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF, Health Qual Life Outcomes 2003 1 13 10.1186/1477-7525-1-13 12773199
8. Standardisation of spirometry. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, Maclntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, Eur Respir J 2005 26 319 338 10.1183/09031936.05.00034805 16055882
9. Forced spirometry reference values for Norwegian adults: the Bronchial Obstruction in Nord-Trondelag Study. Langhammer A, Johnsen R, Gulsvik A, Holmen TL, Bjermer L, Eur Respir J 2001 18 770 779 10.1183/09031936.01.00255301 11757626
10. Difficulties in differential diagnosis of COPD and asthma in primary care. Miravitlles M, Andreu I, Romero Y, Sitjar S, Altes A, Anton E, Br J Gen Pract 2012 62 68 e75 22520766
11. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennaard SI, Rutten-van Molken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF, Eur Respir J 2008 31 416 469 10.1183/09031936.00099306 18238951
12. Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD. Dalal AA, Shah MB, D'Souza AO, Lunacsek OE, Nagar SP, Crater GD, Respir Res 2012 13 41 10.1186/1465-9921-13-41 22651541
13. Is pharmacologic care of chronic obstructive pulmonary disease consistent with the guidelines? Diette GB, Orr P, McCormack MC, Gandy W, Hamar B, Popul Health Manag 2010 13 21 26 10.1089/pop.2008.0048 20158320
14. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, N Engl J Med 2007 356 775 789 10.1056/NEJMoa063070 17314337
15. Asthma, chronic obstructive pulmonary disease, or both? Diagnostic labeling and spirometry in primary care patients aged 40 years or more. Melbye H, Drivenes E, Dalbak LG, Leinan T, Hoegh-Henrichsen S, Ostrem A, Int J Chron Obstruct Pulmon Dis 2011 6 597 603 22135492
16. [Utilization of diagnostic tools and health care services for obstructive lung disease]. Haugan T, Bakken IJ, Storro O, Oien T, Langhammer A, Tidsskr Nor Laegeforen 2008 128 2431 2434 19096464
17. Changed terms for drug payment influenced GPs' diagnoses and prescribing practice for inhaled corticosteroids. Dalbak LG, Rognstad S, Melbye H, Straand J, Eur J Gen Pract 2013 19 106 110 10.3109/13814788.2013.766713 23560809
18. Adapting clinical guidelines to take account of multimorbidity. Guthrie B, Payne K, Alderson P, McMurdo ME, Mercer SW, BMJ 2012 345 6341 10.1136/bmj.e6341 23036829
19. Multimorbidity: time for action rather than words. Salisbury C, Br J Gen Pract 2013 63 64 65 10.3399/bjgp13X661020 23561658
20. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B, Lancet 2012 380 37 43 10.1016/S0140- 6736(12)60240-2 22579043
21. Cardiovascular events in patients with COPD: TORCH study results. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestobo J, Thorax 2010 65 719 725 10.1136/thx.2010.136077 20685748
22. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Nannini LJ, Lasserson TJ, Poole P, Cochrane Database Syst Rev 2012 9 CD006829
23. Withdrawal of inhaled corticosteroids in individuals with COPD-a systematic review and comment on trial methodology. Nadeem NJ, Taylor SJ, Eldridge SM, Respir Res 2011 12 107 10.1186/1465-9921-12-107 21838890
24. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Miravitlles M, Calle M, Soler-Cataluna JJ, Arch Bronconeumol 2012 48 86 98 10.1016/j.arbres.2011.10.007 22196477